United States

Developed Europe

Developed Rest of World

Emerging Markets

Total Internetional

Revenue by Geography

Revenue segments as reported by the company.

Primary Care

Specialty Care

Oncology

Pfizer CentreOne

Vaccines

Hospital

Internal Medicine

Rare Disease

Inflammation & Immunology

Pfizer Ignite

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, informational and administrative expenses

Research and development expenses

Amortization of intangible assets

Restructuring charges and certain acquisition-related costs

Other (income)/deductions

Acquired in-process research and development expenses

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Pfizer

Sildenafil is a medication used to treat erectile dysfunction and pulmonary arterial hypertension. It is sold as the brand name Viagra among others.

Viagra

Atorvastatin is a member of the medication class known as statins, which are used primarily as a lipid-lowering agent and for prevention of events associated with cardiovascular disease. Like all statins, atorvastatin works by inhibiting HMG-CoA reductase, an enzyme found in liver tissue that plays a key role in production of cholesterol in the body. It is marketed under the trade name Lipitor among others

Lipitor

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Pfizer exceeds $100B in revenue, eyes growth amid challenges

Pfizer's exceptional 2022 performance sets the stage for continued success in 2023.
Strategic investments in R&D and new product launches drive revenue growth expectations.
Challenges include transitioning from emergency status and revenue decline from COVID-related products.
Opportunities lie in increased adoption of combo vaccines and business development goals.

Pfizer reports solid Q1 results, eyes growth through innovation

Pfizer's Q1 performance was strong, driven by revenue growth and patient reach.
The company faces challenges in COVID franchise transition and stock performance.
Strategic acquisitions, new product launches, and market monitoring offer growth opportunities.
Pfizer's focus on innovation, trustworthiness, and commercial efficiency underpin its future success.

Pfizer reports Q2 growth amidst COVID uncertainties and therapeutic optimism

Pfizer's Q2 performance reflects growth in non-COVID revenues, strategic acquisitions, and a focus on new product launches. Challenges include uncertainties in revenue forecasts and operational adjustments post-acquisitions. Opportunities lie in therapeutic advancements and the potential of mRNA flu vaccines.

Pfizer reports strong Q3 performance, eyes growth in non-COVID products

Pfizer's Q3 performance showcased resilience in non-COVID product revenue growth, offsetting COVID-related declines. The company's strategic focus on global health impact and innovative acquisitions positions it for future growth. Challenges in the COVID product segment persist, but Pfizer remains optimistic about opportunities in new product launches and cancer treatment advancements.

Pfizer reports solid 2023 performance, eyes growth and cost savings

Pfizer's 2023 performance was strong despite challenges, with a focus on oncology, R&D, and cost savings. The company aims for revenue growth in 2024, emphasizing shareholder value and strategic priorities.

Pfizer reports robust Q1 earnings, eyes international growth and pipeline

Pfizer's Q1 2024 performance showcased strong revenue figures and strategic focus on non-COVID products and oncology, underlining the company's resilience and growth potential.
While facing challenges in adult market contraction and gross margin issues, Pfizer's strengths in pipeline innovation, product performance, and international market growth position it well for the future.
The company's opportunities lie in continued international expansion, consumer engagement initiatives, and upcoming pipeline advancements, signaling a path for sustained growth and innovation.

Pfizer reports strong Q2 earnings, raises guidance amid leadership changes

Pfizer's Q2 2024 earnings call reflects a robust performance, marked by revenue growth, leadership changes, and enhanced guidance. The company's strategic focus on oncology, vaccines, and product differentiation positions it for continued success. Challenges include maintaining market share post-generics and managing growth expectations for VYNDAQEL.

Pfizer reports robust Q3 earnings, eyes international market growth

Pfizer's Q3 earnings call highlighted strong performance, pipeline advancements, and a focus on shareholder value creation. Challenges include addressing the impact of IRA and maintaining growth in specific product lines. Opportunities lie in international market expansion and continued pipeline innovation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Toyota Motor

Social Security faces potential benefit reductions after 2035. Dividend-paying stocks can form a solid basis for a passive income portfolio.

2 Cheap Passive Income Stocks to Buy Now

AstraZeneca

GlaxoSmithKline

Johnson & Johnson

Eli Lilly

Merck

Novo Nordisk

Novartis

Roche Holding AG

Sanofi

In the ever-evolving pharmaceutical landscape, financial stability and business resilience are crucial for long-term success. S&P Global, a leading financial information firm, recently released a comprehensive report evaluating the world's top pharmaceutical companies based on their business and financial risk profiles.

Top 10 pharmaceutical companies in 2024: S&P Global's latest ratings and rankings

JPMorgan Chase & Co

Suncor Energy

Despite broader market indexes reaching new highs, driven mainly by tech stock momentum, many companies have faced plummeting valuations due to worsening macroeconomic conditions.

Time To Buy These 3 Extremely Undervalued Stocks

Pfizer's (PFE) COVID and flu combination vaccine demonstrates a continued trend of higher responses against influenza A but fails to show non-inferiority against the influenza B strain.

Pfizer (PFE), BioNTech COVID-Flu Combo Shot Study Falters

BOTHELL, Wash.—At a recent company town hall here, Pfizer's cancer-business chief looked over some 100 scientists, marketers and other staffers who had just joined the giant drugmaker through a $43 billion acquisition and asked them to reach below their chairs.

Pfizer Is Staking Its Turnaround on Cancer Drugs

BioNTech SE

Pfizer and BioNTech recently reported top-line results from a trial of its combination vaccine that was meant to protect against the flu and COVID-19. The partners' combination shot failed to achieve non-inferiority when compared to an approved flu vaccine.

Pfizer and BioNTech's Combo Shot Missed the Mark. Is It Time to Sell?

Pfizer's revenue grew on a year-over-year basis for the first time in a while. Though a recent acquisition helped, there were other factors that contributed.

Is Pfizer Stock Ready to Bounce Back?

Comcast

Medtronic

Pfizer has a promising pipeline of drugs in development -- tackling cancers and more. Medtronic's 200-plus clinical trials may yield some big revenue generators.

3 Dividend Stocks to Double Up On Right Now

Its combination COVID-19/influenza vaccine fell short of one of its endpoints in a late-stage clinical trial. The U.S. pharmaceutical giant is developing the jab with its European partner BioNTech.

Why Pfizer Stock Slumped on Friday

In trading on Friday, shares of Pfizer were yielding above the 6% mark based on its quarterly dividend (annualized to $1.68), with the stock changing hands as low as $27.85 on the day. Dividends are particularly important for investors to consider, because historically speaking dividends have provided a considerable share of the stock market's total return.

Pfizer Dividend Yield Pushes Past 6%

Shares of Pfizer (PFE) and American depositary receipts (ADRs) of BioNTech (BNTX) dropped in intraday trading Friday following disappointing results from a late-stage study of the drugmakers' combined COVID-19 and flu vaccine in adults.

Pfizer, BioNTech Combination Flu and COVID-19 Shot Misses 1 of 2 Endpoints

Pfizer stock toppled Friday after the pharma giant reported mixed results for its BioNTech-partnered combination flu and Covid vaccine.

Pfizer Slides Toward Sell Zone After BioNTech-Tied Covid/Flu Shot Misses Its Mark

Pfizer Inc. PFE, -0.59% and BioNTech SE BNTX, +2.83% said Friday a Phase 3 trial of their COVID-19-influenza vaccine candidate met one of its two objectives. The companies said the candidate showed “comparable” responses against the SARS-CoV-2 virus when compared with their licensed COVID-19 vaccine, which was one objective.

Pfizer, BioNTech COVID-19-flu combination drug meets 1 of 2 trial objectives

With Pfizer's sales rising in Q2, despite falling sales of Covid-19 products, we think that it may well be the turning point for Pfizer stock. It has seen a decline of 15% from levels of $35 in early January 2021 to around $30 now, vs.

Was Q2 The Turning Point For Pfizer Stock?

Pfizer and BioNTech said a late-stage trial of their experimental mRNA vaccine to protect against influenza and COVID-19 found the combination shot failed to meet one of the study's two main goals and they are evaluating next steps.

Pfizer, BioNtech say combined flu-COVID vaccine misses a main goal of Phase 3 trial

NEW YORK & MAINZ, Germany--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE, “Pfizer”) and BioNTech SE (Nasdaq: BNTX, “BioNTech”) today announced top-line results from their Phase 3 clinical trial to evaluate the companies' combined mRNA vaccine candidate against influenza and COVID-19 in healthy individuals 18-64 years of age. The combination candidate consists of Pfizer's mRNA-based influenza vaccine candidate with the companies' licensed COVID-19 vaccine. The Phase 3 trial measured two primary immuno.

Pfizer and BioNTech Provide Update on mRNA-based Combination Vaccine Program Against Influenza and COVID-19 in Individuals 18-64 Years of Age

Apple Hospitality REIT

Ares Capital

Enel SpA

EPR Properties

Honda

ING Groep NV

Kraft Heinz

Mercedes-Benz Group AG

Altria

NextEra Energy

Northwest Natural Gas

Orkla ASA

TotalEnergies SE

Telefonica Brasil

Verizon

Screening for mid to large-caps, high (>2%) dividends, attractive or neutral rated, >5yr dividend history, positive cash flow stocks as of 8/12/24 data from YCharts revealed 52 potential buy to hold candidates. The resulting list targets investors who “want to simply focus on profitable stocks without the fuss and bother of anything but an annual review and rebalance”. This inquiry will persist for months until a dozen or two truly qualified buy to hold qualifiers are determined from this ongoing search among large, well-established low-volatility and unsinkable companies.

52 Maybe Buy And Hold Stocks From August Dogcatcher Research

Alphabet

Medical Properties Trust

Realty Income Corp

iShares 0-3 Month Treasury Bond ETF

Dividend Harvesting Portfolio saw a rebound after a volatile week in the market, with $13.12 profitability and $19.80 in dividend income generated. New additions to the portfolio include Alphabet, Blackstone Secured Lending Fund, Reaves Utility Income Fund, Ares Capital, PIMCO Dynamic Income Fund, Starwood Property Trust, and Rex AI Equity Premium Income ETF. Forward dividend income stands at $1,648.41 with a 7.78% yield, and the portfolio is in the black by 17.77% ($3,199.47.

Dividend Harvesting Portfolio Week 180: $18,000 Allocated, $1,648.41 In Projected Dividends

British American Tobacco

Lowe's

McDonald's

Procter & Gamble

From a long-term perspective, prolonged and stable returns often lead to dividend stocks. These types of stocks provide constant income and mark strong business fundamentals.

7 Dependable Dividend Stocks for Long-Term Income

The outlook for pharmaceutical stocks has been mixed in the last five years. During the pandemic, the early-movers in the vaccine race gained as compared to others.

3 Pharmaceutical Stocks That Can Surge Higher Even if The Markets Correct

News for Pfizer Stock (PFE)